CVS Health (NYSE:CVS) will release its earnings data before the market opens on Wednesday, February 7th. CVS Health has set its Q4 guidance at $1.88-1.92 EPS.
CVS Health (NYSE:CVS) last issued its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.01. The business had revenue of $46.18 billion during the quarter, compared to analyst estimates of $46.17 billion. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.64 earnings per share. On average, analysts expect CVS Health to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.
Shares of CVS Health (CVS) opened at $80.19 on Wednesday. The company has a quick ratio of 0.55, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The stock has a market cap of $81,230.00, a price-to-earnings ratio of 16.57, a P/E/G ratio of 1.29 and a beta of 0.90. CVS Health has a 12 month low of $66.45 and a 12 month high of $84.00.
The business also recently declared a quarterly dividend, which will be paid on Friday, February 2nd. Investors of record on Wednesday, January 24th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 23rd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.49%. CVS Health’s dividend payout ratio (DPR) is presently 41.32%.
A number of brokerages recently issued reports on CVS. Needham & Company LLC upgraded shares of CVS Health from a “buy” rating to a “strong-buy” rating and lifted their price target for the stock from $88.00 to $100.00 in a research note on Tuesday. Mizuho set a $95.00 price target on shares of CVS Health and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Cowen restated an “outperform” rating and issued a $99.00 price target (up previously from $81.00) on shares of CVS Health in a research note on Thursday, January 18th. Vetr lowered shares of CVS Health from a “hold” rating to a “sell” rating and set a $76.66 price target for the company. in a research note on Tuesday, January 16th. Finally, Leerink Swann boosted their target price on shares of CVS Health from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company. CVS Health currently has an average rating of “Buy” and a consensus price target of $88.06.
In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the sale, the executive vice president now owns 15,556 shares in the company, valued at $1,166,700. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.61% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Fieldpoint Private Securities LLC boosted its holdings in shares of CVS Health by 333.3% during the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after acquiring an additional 1,000 shares during the period. Optimum Investment Advisors boosted its holdings in shares of CVS Health by 20.0% during the second quarter. Optimum Investment Advisors now owns 3,444 shares of the pharmacy operator’s stock valued at $277,000 after acquiring an additional 573 shares during the period. Bluefin Trading LLC acquired a new position in shares of CVS Health during the second quarter valued at $298,000. Keel Point LLC boosted its holdings in shares of CVS Health by 16.0% during the second quarter. Keel Point LLC now owns 3,824 shares of the pharmacy operator’s stock valued at $308,000 after acquiring an additional 528 shares during the period. Finally, Wafra Investment Advisory Group Inc. NY acquired a new stake in CVS Health in the second quarter worth about $507,000. 81.64% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/31/cvs-health-cvs-to-release-earnings-on-wednesday.html.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.